MarketsandMarkets™ has published a new research report titled “Europe Point of Care Diagnostics Market by Product, Purchase Mode, Technology, Sample, and End User – Forecast to 2031” (Report Code: MD 10280). According to the study, the Europe point-of-care (POC) diagnostics market is projected to grow from USD 4.45 billion in 2026 to USD 7.17 billion by 2031, registering a strong CAGR of 10.0% during the forecast period.
The market was valued at USD 4.14 billion in 2025, with growth fueled by the increasing demand for rapid, accurate, and near-patient diagnostic testing, rising prevalence of chronic and infectious diseases, and a growing aging population across Europe.
Decentralized Testing and Home-Based Diagnostics Drive Market Growth
The European healthcare ecosystem is increasingly shifting toward decentralized and community-based care models, accelerating the adoption of point-of-care diagnostics across hospitals, physician offices, pharmacies, retail clinics, and home care settings. The rising use of self-testing solutions, CE-marked diagnostics, and digitally enabled POC platforms is enabling faster clinical decision-making while reducing pressure on centralized laboratories.
Technological advancements that enhance test accuracy, usability, portability, and connectivity with electronic health records are further strengthening adoption across the region. In parallel, healthcare systems are increasingly leveraging POC diagnostics to manage costs, improve patient convenience, and ensure timely diagnosis and treatment.
Key Market Insights
-
By Product: Glucose monitoring products accounted for the largest market share of 43.3% in 2025, driven by the high prevalence of diabetes across Europe.
-
By Mode of Purchase: Prescription-based point-of-care tests dominate the market, reflecting strict regulatory oversight and physician confidence in clinically validated solutions.
-
By Technology: Molecular diagnostics is expected to register the highest CAGR of 11.8%, supported by growing demand for rapid and accurate infectious disease detection.
-
By Sample Type: Blood-based diagnostics are projected to witness the highest growth rate due to their wide applicability in chronic and acute disease monitoring.
-
By End User: Home care settings and self-testing are expected to hold the largest market share, driven by demand for convenient, private, and rapid diagnostic solutions.
UK Emerges as the Fastest-Growing Country Market
Among European countries, the UK is projected to register the highest growth rate (11.8%) during the forecast period. This growth is supported by strong investments in healthcare infrastructure, increased adoption of rapid diagnostic technologies, and a growing focus on early disease detection and decentralized testing models.
Competitive Landscape Highlights
Leading players in the Europe point-of-care diagnostics market include Abbott, Siemens, F. Hoffmann-La Roche Ltd, bioMérieux, and Danaher Corporation. These companies benefit from broad product portfolios, strong installed bases, and continuous innovation in rapid testing platforms and consumables.
Additionally, startups and SMEs such as Response Biomedical and Boditech Med are gaining traction by addressing niche diagnostic needs and expanding access to cost-effective and rapid testing technologies.
Technology Innovation and Regulatory Support Shape Market Outlook
Favorable regulatory frameworks, increased availability of CE-marked and OTC diagnostics, and strong government initiatives supporting infectious disease testing are key enablers of market growth. At the same time, innovations in compact, connected, and user-friendly point-of-care platforms are expanding their use in emergency care, urgent care, and home-based settings across Europe.